Erypharm

What Erypharm does

EryPharm was a private Paris-based biotechnology company founded in 2016 as a spin-off from Sorbonne Université to industrialize research led by Professor Luc Douay on the production of red blood cells from hematopoietic stem cells (HSCs). Its core technology is a six-step industrial cell-culture platform: voluntary donor HSC collection, cryopreservation in nitrogen vapor, a 21-day culture expansion, purification, quality control, and filling into transfusion bags. The process uses non-genetically-modified native HSCs, exploits strong proliferation/differentiation properties, and is positioned to deliver one HSC donation's worth of red blood cells equivalent to ~100 conventional blood donations. The lead product candidate, cultured red blood cells (cRBC/GRc), was developed as a complementary transfusion product for patients with hereditary blood disorders (sickle cell disease, thalassemia) and cancer patients requiring repeated transfusions — populations in which alloimmunization, iron overload, and blood-supply shortages are recurring clinical problems.

EryPharm's commercial model was structured as a regulated biological product: a one-time-per-unit sale (or license-equivalent) of cRBC transfusion units to hospitals, blood banks, and transfusion centers, with distribution planned as direct enterprise sales into healthcare systems post-regulatory approval. The company pursued a clinical-and-regulatory go-to-market motion, having completed preclinical toxicity studies in 2022 and initiated a first clinical trial in 2023, with stated commercial availability targeted for 2030. The platform's competitive pitch rested on quantitative advantages over donor blood: a younger, more homogeneous red-cell population (longer in vivo lifespan), reduced donor-exposure (and thus lower infection/alloimmunization risk), and adjustable production from frozen HSCs to manage demand. Notable institutional anchors included Bpifrance support and the i-Lab Innovation Competition, alongside an ecosystem of French deep-tech partners (Sorbonne, Agoranov, SATT Lutech, Medicen, LEEM).

The company filed no patents in the disclosed data, recognized no certifications, and generated no revenue. Despite reaching the first clinical trial milestone in 2023, EryPharm ceased operations due to lack of funding, leaving its lead asset without a path to commercialization and its 22 employees without a continuation vehicle.

Name

Erypharm

Legal name

EryPharm

Website

https://erypharm.com

Company type

Private

Founded year

2016

Operating status

Closed

Headcount range

11–50 employees

Short description

EryPharm was a Paris-based biotech spin-off from Sorbonne Université developing industrial-scale cultured red blood cells from hematopoietic stem cells for transfusion medicine. Pre-commercial, the company ceased operations due to lack of funding after reaching first-in-human clinical trials.

Ownership category

akta.pro rank

Product category

Cultured Blood Products

NAICS

Scientific Research and Development Services (5417), Blood and Organ Banks (621991)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

akta.pro secondary industries

Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG), Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)

Keywords

• Cultured red blood cells
• Cell therapy biotech
• Hematopoietic stem cells
• Blood transfusion product
• Industrial cell culture

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Cultured Red Blood Cell Product: As a pre-commercial biotech company, Erypharm is developing a biological product (cultured red blood cells) for transfusion purposes. The company ceased operations due to lack of funding and had planned to commercialize the product following clinical trials and regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

EryPharm is developing cultured red blood cells (cRBC) from hematopoietic stem cells through an industrial cell culture process. The product is designed as a complement to traditional blood donation, targeting patients with hereditary blood disorders and cancer who require multiple transfusions. The 21-day production process yields uniformly young red blood cells with longer circulatory lifespan for superior transfusion efficacy.

Product overview

Erypharm offers a single core product: cultured red blood cells (cRBC), produced through an industrial-scale cell culture process from hematopoietic stem cells. The company has developed a 6-step production process involving stem cell collection, cryopreservation, 21-day cell culture, purification, quality control, and storage in transfusion bags. The product aims to address blood supply shortages and improve transfusion efficacy compared to donated blood.

Differentiator

Problem solved

Functional benefit

Products and services

• Cultured Red Blood Cells (cRBC / GRc) Biological product consisting of cultured red blood cells produced from hematopoietic stem cells through an industrial 21-day cell culture process, cryopreserved, purified, quality-controlled, and filled into transfusion bags. Designed as a complement to traditional blood donation for patients requiring multiple transfusions due to hereditary blood disorders or cancer treatment.

Quantifiable outcome

• Transfusion requirements reduced due to superior efficacy of young cRBCs compared to native RBCs
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered supporting and core.

• AgoranovsupportingStrategic or Co-development PartnerBusiness incubator supporting the company's development as a spin-off from academic research
• SATT LutechsupportingStrategic or Co-development PartnerTechnology transfer acceleration company that helped commercialize the academic research from Sorbonne Université
• Sorbonne UniversitécoreStrategic or Co-development PartnerParent academic institution; Erypharm is a spin-off from Sorbonne Université's research conducted by Professor Luc Douay's team. Provides ongoing research collaboration and academic credibility.
• MedicensupportingStrategic or Co-development PartnerFrench competitiveness cluster for innovative health technologies supporting biotech companies in the Paris region
• LEEM (Les Entreprises du Médicament)supportingStrategic or Co-development PartnerFrench pharmaceutical industry association supporting companies in the medicines and biotechnology sector

Scale indicators6 records

Recent moves7 records

Expansion highlights3 records

Direct peers

• Rubius Therapeutics: US biotech that engineered and cultured red blood cells as therapeutic 'Red Cell Therapeutics'; directly comparable in using cultured/engineered RBCs as the core platform, and also notably wound down operations.

Emerging players

• Hemanext: Develops technology to optimize and extend the quality of red blood cell units for transfusion; overlaps on improving RBC transfusion efficacy and shelf life for the same transfusion-medicine market.
• Cellphire Therapeutics: Develops manufactured/freeze-dried blood-derived products (platelets, plasma) for transfusion and hemostasis; comparable as a producer of manufactured blood products addressing supply and storage constraints.

Regional players

• Hemarina: French biotech developing marine-derived universal oxygen carriers as blood/transfusion alternatives; comparable French player tackling blood-supply shortages with an alternative to donated RBCs.

Others

• Etablissement Français du Sang (EFS): France's national blood service that collects, processes and distributes blood products; the incumbent supply channel EryPharm's cultured RBCs would complement or compete with in the same geography.
• NHS Blood and Transplant: UK blood service running the RESTORE lab-grown red blood cell trials; directly relevant as a parallel effort to produce cultured RBCs for transfusion, though as a public institution rather than a commercial peer.
• Gamida Cell: Develops cell therapies expanded from hematopoietic stem/progenitor cells; comparable in HSC-based ex vivo expansion technology applied to hematologic indications.
• Vor Biopharma: Engineers hematopoietic stem cells for hematologic disease; shares the HSC-processing and cell-engineering technology base, though aimed at transplant/oncology rather than transfusion.
• Vitalant: Large US blood collection and supply organization; represents the conventional donor-based transfusion supply that cultured RBC products aim to supplement.
• Magenta Therapeutics: Developed HSC mobilization and conditioning technologies for stem cell transplant; adjacent in the hematopoietic stem cell domain that underpins EryPharm's process.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/EryPharm

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Erypharm